Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?
10:25am, Thursday, 09'th Oct 2025
Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know
01:01pm, Wednesday, 08'th Oct 2025
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know
10:55am, Wednesday, 08'th Oct 2025
The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 08'th Oct 2025
Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
1 Stock Up by 63% This Year That Could Double, According to Wall Street
09:45am, Tuesday, 07'th Oct 2025
Shares of Intellia Therapeutics (NTLA -0.29%), a small-cap biotech company, are up by 63% this year. The company is benefiting from substantial clinical progress, and judging by price targets set by W
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 03'rd Oct 2025
CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought
10:47am, Wednesday, 01'st Oct 2025
Cathie Wood is having a good year. The Ark Invest founder, CEO, and ace stock picker isn't back to her peak 2020 form when many of her exchange-traded funds (ETFs) more than doubled in value.
Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug
01:57pm, Thursday, 25'th Sep 2025
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary
CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
02:31pm, Friday, 19'th Sep 2025
News shared this week that Intellia Therapeutics, Inc.'s pivotal study of candidate lonvo-z is fully enrolled has been greeted warmly by the market, with good reason. NTLA stock remains a compelling B
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
01:26pm, Friday, 19'th Sep 2025
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?
10:21am, Friday, 19'th Sep 2025
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
2 More Stocks With 1,000% Upside
12:00pm, Sunday, 14'th Sep 2025
Tom Yeung here with your Sunday Digest . Almost every multimillionaire investor I know has their version of “The One” – a single investment that built much of their wealth.
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
03:45am, Thursday, 11'th Sep 2025
Cathie Wood is known for seizing opportunities. The founder of Ark Invest doesn't worry when one of the stocks she's invested in drops, and instead, she looks at the movement as a chance to increase h
